Hervorgehoben
JAHRESPARTNER
AKTUELLES
Where to next after the Gilead-Tubulis deal?
Gilead’s acquisition of Munich-based Tubulis earlier this year has put German antibody-drug conjugate (ADC) innovation into the global spotlight. With a total deal value of up to USD 5 billion, it was a landmark...
The dual-use dilemma in biotechnology
When a single internal, non-invasive sensing platform can continuously capture physiological data from an athlete during training/game and simultaneously monitor a special forces operator’s vital state in demanding operational environments, the technology itself does...
From algorithms to patient care: Hannover’s AI ecosystem
AI only transforms medicine once innovations reach the point of care. The Hannover region offers strong foundations for this: research, clinical care, business, and politics work closely together here. Networks such as the Health...
Elevatry sammelt 3 Mio. Euro für KI-Plattform im Einkauf ein
Das Münchner Start-up Elevatry hat eine Pre-Seed-Finanzierung über 3 Mio. EUR abgeschlossen. Zu den Investoren zählen Bayern Kapital, die Unternehmensberatung H&Z sowie mehrere Business Angels, darunter Jan Henner-Theißen, Martin Berr-Sorokin, Mike Simon, Markus Ehrle,...
Bridging academia and industry
German research institutions produce world-class science, yet university spin-offs continue to face a practical bottleneck: securing intellectual property (IP) on terms that founders and investors can evaluate before committing capital. The German Spin-off Framework...
seragy erhält 12 Mio. EUR für Biomarkerentwicklung
Das Biotechnologieunternehmen seragy holding GmbH (ehem. Prosperodes GmbH) hat sich eine Finanzierung in Höhe von 12 Mio. EUR gesichert. Mit dem Kapital will das Unternehmen seine SeRAS®-Technologie weiterentwickeln, die Labor- und Analysekapazitäten ausbauen und...